
Seagen (SGEN) Stock Forecast & Price Target
Seagen (SGEN) Analyst Ratings
Bulls say
Seagen is a well-established company with marketable therapies for a variety of cancers, combined with a strong licensing program for its antibody-drug conjugate technology. Its lead product Adcetris has received approval for six indications to treat Hodgkin lymphoma and T-cell lymphoma, while its newly approved product Padcev, when combined with Keytruda, nearly doubled the PFS & OS seen with a chemotherapeutic approach. EV-302 data from the Phase 3KEYNOTE-A39/EV-302 study was also promising, providing grounds for acceleration approval in April of 2023. This, combined with Seagen's strong financials and key data metrics, make the company an attractive investment for the long term.
Bears say
Seagen is generating strong revenue from its products, but has limited pipeline upside to drive sustained long-term growth. Research and Development spending has significantly increased in recent quarters, while profits remain marginal. Cash flow has decreased in the past few years, indicating that the current level of growth may not be sustainable. As a result, Seagen's valuation is likely to remain under pressure in the near-term.
This aggregate rating is based on analysts' research of Seagen and is not a guaranteed prediction by Public.com or investment advice.
Seagen (SGEN) Analyst Forecast & Price Prediction
Start investing in Seagen (SGEN)
Order type
Buy in
Order amount
Est. shares
0 shares